Published in Cancer Weekly, May 26th, 2009
"A major effector of PI3K is Akt/protein kinase B (PKB). Recent studies have pointed to distinct roles of Akt/PKB Isoforms in cancer cell signaling. Studies have shown that Akt1 (PKB alpha) can attenuate breast cancer cell motility, whereas Akt2 (PKB beta) enhances this phenotype. Here, we have evaluated the mechanism by which Akt1 blocks the migration of breast cancer cells through the transcription factor NFAT. A major effector of Akt/PKB Is glycogen synthase kInase-3...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.